Hormonal
Chronic sleep restriction (4-5 hours/night) significantly reduces insulin sensitivity and increases diabetes risk in healthy adults.
Prioritize getting 7-9 hours of sleep nightly. Chronic sleep restriction (4-5 hours) significantly impairs your body's ability to process glucose and increases insulin resistance, mimicking the metabolic state of obesity or diabetes. Consistent sleep duration is as critical for metabolic health as diet and exercise.
Remarkably, insulin sensitivity as well as disposition index, a marker of diabetes risk, were significantly decreased in the sleep loss condition.
Why this rating
Based on controlled laboratory studies with intravenous glucose tolerance tests and adipocyte biopsies, though sample sizes are small.
Source
Impact of Sleep and Circadian Disruption on Energy Balance and Diabetes: A Summary of Workshop Discussions
Deanna M. Arble et al. · SLEEP · 2015
DOI 10.5665/sleep.5226
More from this paper
- Circadian misalignment (desynchrony between sleep/eating times and internal clocks) independently reduces insulin sensitivity and exacerbates the negative metabolic effects of sleep restriction.Good
- Continuous Positive Airway Pressure (CPAP) treatment for Obstructive Sleep Apnea (OSA) improves insulin resistance in patients without diabetes.Moderate
- Time-Restricted Feeding (TRF) aligned with the active period improves metabolic health markers (body weight, cholesterol, insulin levels) in mice without reducing overall food intake.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →